Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Marta Iruarrizaga"'
Autor:
Maria Azparren‐Angulo, Justyna Mleczko, Oihane E. Alboniga, Sergei Kruglik, Jean‐Michel Guigner, Esperanza Gonzalez, Clara Garcia‐Vallicrosa, Jordi Llop, Cristina Simó, Cristina Alonso, Marta Iruarrizaga, Felix Royo, Juan M. Falcon‐Perez
Publikováno v:
Journal of Extracellular Biology, Vol 3, Iss 2, Pp n/a-n/a (2024)
Abstract Extracellular vesicles (EVs) have been involved in metabolic syndrome, although their specific role in the development of the pathology is still unknown. To further study the role of EVs, we have analysed by Raman tweezers microspectroscopy
Externí odkaz:
https://doaj.org/article/abd49f41b79c4515bbbe878f208d276b
Autor:
Anita M. van denHoek, Elsbet J. Pieterman, José W. van derHoorn, Marta Iruarrizaga‐Lejarreta, Cristina Alonso, Lars Verschuren, Tore Skjæret, Hans M.G. Princen, David A. Fraser
Publikováno v:
Hepatology Communications, Vol 4, Iss 2, Pp 193-207 (2020)
Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH). In this study, we investigated the absorption and distribution properties of icosabutate in relation to liver targeti
Externí odkaz:
https://doaj.org/article/17635485619345adb907554abe0b690f
Autor:
Christopher J. Mowry, MD, Cristina Alonso, PhD, Marta Iruarrizaga-Lejarreta, PhD, Pablo Ortiz, MD, PhD, Josh Levitsky, MD, MS, Mary Rinella, MD
Publikováno v:
Transplantation Direct, Vol 7, Iss 12, p e784 (2021)
Background. Nonalcoholic fatty liver disease (NAFLD) is a rising indication for liver transplantation (LT). Identification of NAFLD recurrence and those at risk for more progressive disease after LT remains elusive as the diagnosis requires biopsy, w
Externí odkaz:
https://doaj.org/article/7d381d77ca3448e398a9f05fef8fee10
Autor:
Martine C. Morrison, Lars Verschuren, Kanita Salic, Joanne Verheij, Aswin Menke, Peter Y. Wielinga, Marta Iruarrizaga‐Lejarreta, Laurent Gole, Wei‐Miao Yu, Scott Turner, Martien P.M. Caspers, Ibon Martínez‐Arranz, Elsbet Pieterman, Reinout Stoop, Arianne van Koppen, Anita M. van den Hoek, José M. Mato, Roeland Hanemaaijer, Cristina Alonso, Robert Kleemann
Publikováno v:
Hepatology Communications, Vol 2, Iss 12, Pp 1513-1532 (2018)
Concerns have been raised about whether preclinical models sufficiently mimic molecular disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into question their translational value in studies of therapeutic interventio
Externí odkaz:
https://doaj.org/article/b7dbea0375ad493383bf24d4d1bb040c
Autor:
Joaquín Fernández-Irigoyen, Paz Cartas-Cejudo, Marta Iruarrizaga-Lejarreta, Enrique Santamaría
Publikováno v:
Biomedicines, Vol 9, Iss 5, p 491 (2021)
Lipid metabolism is clearly associated to Parkinson’s disease (PD). Although lipid homeostasis has been widely studied in multiple animal and cellular models, as well as in blood derived from PD individuals, the cerebrospinal fluid (CSF) lipidomic
Externí odkaz:
https://doaj.org/article/d32aacbc1497480190c962cfa244c245
Autor:
Vanesa Flores, Mireia Mora, Gemma Rojo, Felicia A. Hanzu, Ting Hu, Francesc Carmona, Oriol Giró, Guillermo Garcia-Eguren, Gloria Aranda, Marta Iruarrizaga, Ramon Gomis, Arturo Vega-Beyhart, Gregori Casals, Adriana Pané, Laura Boswell, Cristina Alonso, Joaquim Enseñat, Irene Halperin, Oscar Vidal
Publikováno v:
Journal of Molecular Medicine. 99:1085-1099
Chronic cortisol excess induces several alterations on protein, lipid and carbohydrate metabolism resembling those found in the metabolic syndrome. However, patients exposed to prolonged high levels of cortisol in Cushing syndrome (CS) present exceed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca6fc536f5a278fe47c3983adb506e3
https://doi.org/10.1007/s00109-021-02076-0
https://doi.org/10.1007/s00109-021-02076-0
Autor:
David A. Fraser, Xiaoyu Wang, Jenny Lund, Nataša Nikolić, Marta Iruarrizaga-Lejarreta, Tore Skjaeret, Cristina Alonso, John J.P. Kastelein, Arild C. Rustan, Yong Ook Kim, Detlef Schuppan
Publikováno v:
Journal of hepatology, 76(4), 800-811. Elsevier
Background & Aims: Although long-chain omega-3 fatty acids (LCn-3FAs) regulate inflammatory pathways of relevance to non-alcoholic steatohepatitis (NASH), their susceptibility to peroxidation may limit their therapeutic potential. We compared the met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24bb34640194cc100454542ea670cf9b
https://pure.amc.nl/en/publications/a-structurally-engineered-fatty-acid-icosabutate-suppresses-liver-inflammation-and-fibrosis-in-nash(f9db8dc2-fa29-42cc-b2b8-ea1f1a47881f).html
https://pure.amc.nl/en/publications/a-structurally-engineered-fatty-acid-icosabutate-suppresses-liver-inflammation-and-fibrosis-in-nash(f9db8dc2-fa29-42cc-b2b8-ea1f1a47881f).html
Autor:
Patrick C.N. Rensen, Geurt Stokman, Hans M.G. Princen, Michael Feigh, Marta Iruarrizaga-Lejarreta, José W.A. van der Hoorn, Ditte Denker Thorbekk, John J.P. Kastelein, Sanne Skovgård Veidal, Elsbet J. Pieterman, Lars Verschuren, David A. Fraser, Cristina Alonso, Scott L. Friedman, Brittany Basta, Tore Skjaeret, Anita M. van den Hoek, Jimmy F.P. Berbée
Publikováno v:
Liver International
Liver International, 40(11), 2860-2876. WILEY
Liver International, 40(11), 2860-2876. WILEY
Background & Aims While fibrosis stage predicts liver‐associated mortality, cardiovascular disease (CVD) is still the major overall cause of mortality in patients with NASH. Novel NASH drugs should thus ideally reduce both liver fibrosis and CVD. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5dde65642a000592115aac1140f902d
https://doi.org/10.1111/liv.14643
https://doi.org/10.1111/liv.14643
Autor:
Ibon Martínez‐Arranz, Chiara Bruzzone, Mazen Noureddin, Ruben Gil‐Redondo, Itziar Mincholé, Maider Bizkarguenaga, Enara Arretxe, Marta Iruarrizaga‐Lejarreta, David Fernández‐Ramos, Fernando Lopitz‐Otsoa, Rebeca Mayo, Nieves Embade, Elizabeth Newberry, Bettina Mittendorf, Laura Izquierdo‐Sánchez, Vaclav Smid, Jorge Arnold, Paula Iruzubieta, Ylenia Pérez Castaño, Marcin Krawczyk, Urko M. Marigorta, Martine C. Morrison, Robert Kleemann, Antonio Martín‐Duce, Liat Hayardeny, Libor Vitek, Radan Bruha, Rocío Aller de la Fuente, Javier Crespo, Manuel Romero‐Gomez, Jesus M Banales, Marco Arrese, Kenneth Cusi, Elisabetta Bugianesi, Samuel Klein, Shelly C. Lu, Quentin M. Anstee, Oscar Millet, Nicholas O. Davidson, Cristina Alonso, José M. Mato
Publikováno v:
Hepatology (Baltimore, Md.), vol 76, iss 4
Hepatology . 2022 Oct;76(4):1121-1134
Hepatology . 2022 Oct;76(4):1121-1134
Background and aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and results: We analyzed serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df9a8bd626dbb9830cfeced7bc528e7e
http://hdl.handle.net/2318/1874441
http://hdl.handle.net/2318/1874441
Autor:
Marta Iruarrizaga-Lejarreta, Anita M. van den Hoek, Elsbet J. Pieterman, José W.A. van der Hoorn, Lars Verschuren, David A. Fraser, Tore Skjaeret, Hans M.G. Princen, Cristina Alonso
Publikováno v:
Hepatology Communications, Vol 4, Iss 2, Pp 193-207 (2020)
Hepatology Communications
Hepatology Communications
Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH). In this study, we investigated the absorption and distribution properties of icosabutate in relation to liver targeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aa5ba4191673e6e21030ba1af470b22
https://doi.org/10.1002/hep4.1453
https://doi.org/10.1002/hep4.1453